Alteplase News
Intraclot alteplase injection an option for treating lower extremity DVT
As an alternative to continuous-infusion thrombolytic regimens, direct intraclot injection of alteplase is a suitable treatment for deep vein thrombosis (DVT) of the lower extremity that limits systemic exposure to thrombolytic...
Study Suggests Thrombolysis Therapy With Alteplase Could Be Used Routinely for Stroke Treatment
The thrombolytic drug alteplase, despite recent concerns, is safe and effective in routine clinical use when used within 3 hours of stroke onset, according to an observational study published in this week's issue of The Lancet.
Investors Dump Nuvelo On Alfimeprase's Phase III Data
Bad news for Nuvelo Inc.: Its partnered thrombolytic drug alfimeprase failed two Phase III studies, one in acute peripheral arterial occlusion (PAO) and the other in catheter occlusion (CO).
Asymptomatic Hemorrhage After Thrombolysis May Not Be Benign. Prognosis by Hemorrhage Type in the Canadian Alteplase for Stroke Effectiveness Study Registry.
BACKGROUND AND PURPOSE: There is ongoing controversy about the impact of hemorrhagic transformation after thrombolysis on long-term functional outcome. We sought to study the relation between the type of hemorrhagic...
Alteplase for the Treatment of Central Venous Catheter Occlusion in Children: Results of a Prospective, Open-label, Single-arm Study (The Cathflo Activase Pediatric Study).
PURPOSE: Alteplase is approved for use in the restoration of function to occluded central venous access devices (CVADs); however, there are few prospective studies in children. This study was undertaken to evaluate the safety and...